


AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

1. **(currently amended):** A method for inhibiting CCR3, comprising administering to a subject an effective amount of a compound having CCR3 antagonistic activity, wherein said compound is ~~A pharmaceutical composition which contains, as an active ingredient, a compound~~ represented by the following formula (I), a pharmaceutically acceptable acid addition salt thereof, or a pharmaceutically acceptable C₁ to C₆ alkyl addition salt thereof, ~~and which has CCR3 antagonistic activity,~~



{wherein, R¹ represents a phenyl group, a C₃ to C₈ cycloalkyl group, or an aromatic heterocyclic group having one to three atoms of oxygen, sulfur and/or nitrogen as heteroatoms, provided that the phenyl group or the aromatic heterocyclic group in the above-mentioned R¹ may be condensed with a benzene ring, or an aromatic heterocyclic group having one to three atoms of oxygen, sulfur and/or nitrogen as heteroatoms to form a condensed ring, further provided that the phenyl group, the C₃ to C₈ cycloalkyl group, the aromatic heterocyclic group or the condensed ring may be substituted by one or more ~~the arbitrary number of~~ halogen atoms, hydroxy groups, cyano groups, nitro groups, carboxyl groups, carbamoyl groups, C₁ to C₆ alkyl

groups, C₃ to C₈ cycloalkyl groups, C₂ to C₆ alkenyl groups, C₁ to C₆ alkoxy groups, C₁ to C₆ alkylthio groups, C₃ to C₅ alkylene groups, C₂ to C₄ alkyleneoxy groups, C₁ to C₃ alkylenedioxy groups, phenyl groups, phenoxy groups, phenylthio groups, benzyl groups, benzyloxy groups, benzoylamino groups, C₂ to C₇ alkanoyl groups, C₂ to C₇ alkoxycarbonyl groups, C₂ to C₇ alkanoyloxy groups, C₂ to C₇ alkanoylamino groups, C₂ to C₇ N-alkylcarbamoyl groups, C₄ to C₉ N-cycloalkylcarbamoyl groups, C₁ to C₆ alkylsulfonyl groups, C₃ to C₈ (alkoxycarbonyl)methyl groups, N-phenylcarbamoyl groups, piperidinocarbonyl groups, morpholinocarbonyl groups, 1-pyrrolidinylcarbonyl groups, divalent groups represented by the formula: -NH(C=O)O-, divalent groups represented by the formula: -NH(C=S)O-, amino groups, mono(C₁ to C₆ alkyl)amino groups or di(C₁ to C₆ alkyl)amino groups, and further provided that the substituents of the phenyl group, the C₃ to C₈ cycloalkyl group, the aromatic heterocyclic group or the condensed ring may further be substituted by one or more ~~the arbitrary number of~~ halogen atoms, hydroxy groups, amino groups, trifluoromethyl groups, C₁ to C₆ alkyl groups or C₁ to C₆ alkoxy groups; ~~groups.~~

R² represents a hydrogen atom, a C₁ to C₆ alkyl group, a C₂ to C₇ alkoxycarbonyl group, a hydroxy group or a phenyl group, provided that the C₁ to C₆ alkyl group or the phenyl group in R² may be substituted by one or more ~~the arbitrary number of~~ halogen atoms, hydroxy groups, C₁ to C₆ alkyl groups or C₁ to C₆ alkoxy groups, and provided that when j is 0, R² is not a hydroxy group; ~~group.~~

j represents an integer of 0 to 2; ~~2.~~

k represents an integer of 0 to 2; ~~2.~~

m represents an integer of 2 to 4; ~~4.~~

n represents 0 or 1; ~~1~~.

R³ represents a hydrogen atom or a C₁ to C₆ alkyl group which may be substituted by one or two phenyl groups which may be substituted by the same or different ~~arbitrary~~ numbers of halogen atoms, hydroxy groups, C₁ to C₆ alkyl groups or C₁ to C₆ alkoxy groups; ~~groups~~, ~~respectively~~).

R⁴ and R⁵, which may be the same or differently, represent a hydrogen atom, a hydroxy group, a phenyl group or a C₁ to C₆ alkyl group, ~~respectively~~, and the C₁ to C₆ alkyl group represented by R⁴ and/or R⁵ may be substituted by one or more ~~the arbitrary number~~ of halogen atoms, hydroxy groups, cyano groups, nitro groups, carboxyl groups, carbamoyl groups, mercapto groups, guanidino groups, C₃ to C₈ cycloalkyl groups, C₁ to C₆ alkoxy groups, C₁ to C₆ alkylthio groups, phenyl groups (which may be substituted by one or more ~~the arbitrary number~~ of halogen atoms, hydroxy groups, C₁ to C₆ alkyl groups, C₁ to C₆ alkoxy groups or benzyloxy groups, phenoxy groups, benzyloxy groups, benzyloxycarbonyl groups, C₂ to C₇ alkanoyl groups, C₂ to C₇ alkoxycarbonyl groups, C₂ to C₇ alkanoyloxy groups, C₂ to C₇ alkanoylamino groups, C₂ to C₇ N-alkylcarbamoyl groups, C₁ to C₆ alkylsulfonyl groups, amino groups, mono(C₁ to C₆ alkyl)amino groups, di(C₁ to C₆ alkyl)amino groups or aromatic heterocyclic groups (having one to three atoms of oxygen, sulfur and/or nitrogen as heteroatoms), or condensed rings formed by the condensation of the aromatic heterocyclic group with a benzene ring, or R⁴ and R⁵ may together form a three to six-membered cyclic hydrocarbon; ~~hydrocarbon~~.

p represents 0 or 1; ~~1~~.

q represents 0 or 1; ~~1~~.

G represents a group represented by -CO-, -SO₂-, -CO-O-, -NR⁷-CO-, -CO-NR⁷-, -NH-CO-NH-, -NH-CS-NH-, -NR⁷-SO₂-, -SO₂-NR⁷-, -NH-CO-O-, or -O-CO-NH-, provided that R⁷ is a hydrogen atom or a C₁ to C₆ alkyl group, or R⁷ may form a C₂ to C₅ alkylene group together with R⁵, R⁵.

R⁶ represents a phenyl group, a C₃ to C₈ cycloalkyl group, a C₃ to C₆ cycloalkenyl group, a benzyl group or an aromatic heterocyclic group having one to three atoms of oxygen, sulfur and/or nitrogen as heteroatoms, provided that the phenyl group, the benzyl group or the aromatic heterocyclic group represented by in the above mentioned R⁶ may be condensed, to make a condensed ring, with a benzene ring or an aromatic heterocyclic group having one or three atoms of oxygen, sulfur and/or nitrogen as heteroatoms, further provided that the phenyl group, the C₃ to C₈ cycloalkyl group, the C₃ to C₆ cycloalkenyl group, the benzyl group, the aromatic heterocyclic group or the condensed ring represented by in the above mentioned R⁶ may be substituted by one or more the arbitrary number of halogen atoms, hydroxy groups, mercapto groups, cyano groups, nitro groups, thiocyanato groups, carboxyl groups, carbamoyl groups, trifluoromethyl groups, C₁ to C₆ alkyl groups, C₃ to C₆ cycloalkyl groups, C₂ to C₆ alkenyl groups, C₁ to C₆ alkoxy groups, C₃ to C₈ cycloalkyloxy groups, C₁ to C₆ alkylthio groups, C₁ to C₃ alkylenedioxy groups, phenyl groups, phenoxy groups, phenylamino groups, benzyl groups, benzoyl groups, phenylsulfinyl groups, phenylsulfonyl groups, 3-phenylureido groups, C₂ to C₇ alkanoyl groups, C₂ to C₇ alkoxycarbonyl groups, C₂ to C₇ alkanoyloxy groups, C₂ to C₇ alkanoylamino group, C₂ to C₇ N-alkylcarbamoyl groups, C₁ to C₆ alkylsulfonyl groups, phenylcarbamoyl groups, N,N-di(C₁ to C₆ alkyl)sulfamoyl groups, amino groups, mono(C₁ to C₆

alkyl)amino groups, di(C₁ to C₆ alkyl)amino groups, benzylamino groups, C₂ to C₇ (alkoxycarbonyl)amino groups, C₁ to C₆ (alkylsulfonyl)amino groups or bis(C₁ to C₆ alkylsulfonyl)amino groups, and further provided that the substituents of the phenyl group, the C₃ to C₈ cycloalkyl group, the C₃ to C₈ cycloalkenyl group, the benzyl group, the aromatic heterocyclic group, or the condensed ring may further be substituted by one or more ~~the arbitrary number of~~ halogen atoms, cyano groups, hydroxy groups, amino groups, trifluoromethyl groups, C₁ to C₆ alkyl groups, C₁ to C₆ alkoxy groups, C₁ to C₆ alkylthio groups, mono(C₁ to C₆ alkyl)amino groups, or di(C₁ to C₆ alkyl)amino groups; and
wherein when k is 1 and m is 2, then n is not 1.

2. **(currently amended):** The method ~~pharmaceutical composition having the CCR3 antagonistic action~~ according to Claim 1, wherein k is 1 and m is 2 in the above-mentioned formula (I).

3. **(withdrawn):** The method ~~pharmaceutical composition having the CCR3 antagonistic action~~ according to Claim 1, wherein k is 0 and m is 3 in the above-mentioned formula (I).

4. **(withdrawn):** The method ~~pharmaceutical composition having the CCR3 antagonistic action~~ according to Claim 1, wherein k is 1 and m is 3 in the above-mentioned formula (I).

5. **(withdrawn):** The method pharmaceutical composition having the CCR3 antagonistic action according to Claim 1, wherein k is 2 and m is 2 in the above-mentioned formula (I).

6. **(withdrawn):** The method according to Claim 1, wherein k is 1 and m is 4 in the above-mentioned formula (I).

7. **(currently amended):** A method for treatment and/or prevention of allergic disease, asthma, allergic rhinitis, atopic dermatitis, urticaria, contact dermatitis, allergic conjunctivitis, inflammatory bowel disease, ulcerative colitis, Crohn disease, eosinophilia, eosinophilic gastroenteritis, eosinophilic enteropathy, eosinophilic fasciitis, eosinophilic granuloma, eosinophilic pustular folliculitis, eosinophilic pneumonia, eosinophilic leukemia, and Acquired Immuno-Deficiency Syndrome (AIDS), comprising administering to a subject pharmaceutical composition which contains, as an active ingredient, an effective amount of a compound having CCR3 antagonistic activity, wherein said the compound is represented by the above-mentioned formula (I), the pharmaceutically acceptable acid addition salt thereof, or the pharmaceutically acceptable C1 to C6 alkyl addition salt thereof, and which is used for treating or preventing a disease concerned with CCR3.

wherein, R¹ represents a phenyl group, a C₃ to C₈ cycloalkyl group, or an aromatic heterocyclic group having one to three atoms of oxygen, sulfur and/or nitrogen as heteroatoms, provided that the phenyl group or the aromatic heterocyclic group in the above-mentioned R¹ may be condensed with a benzene ring, or an aromatic heterocyclic group having one to three

atoms of oxygen, sulfur and/or nitrogen as heteroatoms to form a condensed ring, further provided that the phenyl group, the C₃ to C₈ cycloalkyl group, the aromatic heterocyclic group or the condensed ring may be substituted by one or more halogen atoms, hydroxy groups, cyano groups, nitro groups, carboxyl groups, carbamoyl groups, C₁ to C₆ alkyl groups, C₃ to C₈ cycloalkyl groups, C₂ to C₆ alkenyl groups, C₁ to C₆ alkoxy groups, C₁ to C₆ alkylthio groups, C₃ to C₅ alkylene groups, C₂ to C₄ alkyleneoxy groups, C₁ to C₃ alkylendioxy groups, phenyl groups, phenoxy groups, phenylthio groups, benzyl groups, benzyloxy groups, benzoylamino groups, C₂ to C₇ alkanoyl groups, C₂ to C₇ alkoxycarbonyl groups, C₂ to C₇ alkanoyloxy groups, C₂ to C₇ alkanoylamino groups, C₂ to C₇ N-alkylcarbamoyl groups, C₄ to C₉ N-cycloalkylcarbamoyl groups, C₁ to C₆ alkylsulfonyl groups, C₃ to C₈ (alkoxycarbonyl)methyl groups, N-phenylcarbamoyl groups, piperidinocarbonyl groups, morpholinocarbonyl groups, 1-pyrrolidinylcarbonyl groups, divalent groups represented by the formula: -NH(C=O)O-, divalent groups represented by the formula: -NH(C=S)O-, amino groups, mono(C₁ to C₆ alkyl)amino groups or di(C₁ to C₆ alkyl)amino groups, and further provided that the substituents of the phenyl group, the C₃ to C₈ cycloalkyl group, the aromatic heterocyclic group or the condensed ring may further be substituted by one or more the arbitrary number of halogen atoms, hydroxy groups, amino groups, trifluoromethyl groups, C₁ to C₆ alkyl groups or C₁ to C₆ alkoxy groups; groups.

R² represents a hydrogen atom, a C₁ to C₆ alkyl group, a C₂ to C₇ alkoxycarbonyl group, a hydroxy group or a phenyl group, provided that the C₁ to C₆ alkyl group or the phenyl group in R² may be substituted by one or more halogen atoms, hydroxy groups, C₁ to C₆ alkyl groups or C₁ to C₆ alkoxy groups, and provided that when j is 0, R² is not a hydroxy group;

j represents an integer of 0 to 2;

k represents an integer of 0 to 2;

m represents an integer of 2 to 4;

n represents 0 or 1;

R³ represents a hydrogen atom or a C₁ to C₆ alkyl group which may be substituted by one or two phenyl groups which may be substituted by the same or different numbers of halogen atoms, hydroxy groups, C₁ to C₆ alkyl groups or C₁ to C₆ alkoxy groups;

R⁴ and R⁵, which may be the same or different, represent a hydrogen atom, a hydroxy group, a phenyl group or a C₁ to C₆ alkyl group, and the C₁ to C₆ alkyl group represented by R⁴ and/or R⁵ may be substituted by one or more halogen atoms, hydroxy groups, cyano groups, nitro groups, carboxyl groups, carbamoyl groups, mercapto groups, guanidino groups, C₃ to C₈ cycloalkyl groups, C₁ to C₆ alkoxy groups, C₁ to C₆ alkylthio groups, phenyl groups which may be substituted by one or more halogen atoms, hydroxy groups, C₁ to C₆ alkyl groups, C₁ to C₆ alkoxy groups or benzyloxy groups, phenoxy groups, benzyloxy groups, benzyloxycarbonyl groups, C₂ to C₇ alkanoyl groups, C₂ to C₇ alkoxycarbonyl groups, C₂ to C₇ alkanoyloxy groups, C₂ to C₇ alkanoylamino groups, C₂ to C₇ N-alkylcarbamoyl groups, C₁ to C₆ alkylsulfonyl groups, amino groups, mono(C₁ to C₆ alkyl)amino groups, di(C₁ to C₆ alkyl)amino groups or aromatic heterocyclic groups (having one to three atoms of oxygen, sulfur and/or nitrogen as heteroatoms), or condensed rings formed by the condensation of the aromatic heterocyclic group with a benzene ring, or R⁴ and R⁵ may together form a three to six-membered cyclic hydrocarbon;

p represents 0 or 1;

q represents 0 or 1;

G represents a group represented by -CO-, -SO₂-, -CO-O-, -NR⁷-CO-, -CO-NR⁷-, -NH-CO-NH-, -NH-CS-NH-, -NR⁷-SO₂-, -SO₂-NR⁷-, -NH-CO-O-, or -O-CO-NH-, provided that R⁷ is a hydrogen atom or a C₁ to C₆ alkyl group, or R⁷ may form a C₂ to C₅ alkylene group together with R⁵;

R⁶ represents a phenyl group, a C₃ to C₈ cycloalkyl group, a C₃ to C₆ cycloalkenyl group, a benzyl group or an aromatic heterocyclic group having one to three atoms of oxygen, sulfur and/or nitrogen as heteroatoms, provided that the phenyl group, the benzyl group or the aromatic heterocyclic group represented by R⁶ may be condensed, to make a condensed ring, with a benzene ring or an aromatic heterocyclic group having one or three atoms of oxygen, sulfur and/or nitrogen as heteroatoms, further provided that the phenyl group, the C₃ to C₈ cycloalkyl group, the C₃ to C₆ cycloalkenyl group, the benzyl group, the aromatic heterocyclic group or the condensed ring represented by R⁶ may be substituted by one or more halogen atoms, hydroxy groups, mercapto groups, cyano groups, nitro groups, thiocyanato groups, carboxyl groups, carbamoyl groups, trifluoromethyl groups, C₁ to C₆ alkyl groups, C₃ to C₆ cycloalkyl groups, C₂ to C₆ alkenyl groups, C₁ to C₆ alkoxy groups, C₃ to C₈ cycloalkyloxy groups, C₁ to C₆ alkylthio groups, C₁ to C₃ alkylenedioxy groups, phenyl groups, phenoxy groups, phenylamino groups, benzyl groups, benzoyl groups, phenylsulfinyl groups, phenylsulfonyl groups, 3-phenylureido groups, C₂ to C₇ alkanoyl groups, C₂ to C₇ alkoxycarbonyl groups, C₂ to C₇ alkanoyloxy groups, C₂ to C₇ alkanoylamino group, C₂ to C₇ N-alkylcarbamoyl groups, C₁ to C₆ alkylsulfonyl groups,

phenylcarbamoyl groups, N,N-di(C₁ to C₆ alkyl)sulfamoyl groups, amino groups, mono(C₁ to C₆ alkyl)amino groups, di(C₁ to C₆ alkyl)amino groups, benzylamino groups, C₂ to C₇ (alkoxycarbonyl)amino groups, C₁ to C₆ (alkylsulfonyl)amino groups or bis(C₁ to C₆ alkylsulfonyl)amino groups, and further provided that the substituents of the phenyl group, the C₃ to C₈ cycloalkyl group, the C₃ to C₈ cycloalkenyl group, the benzyl group, the aromatic heterocyclic group, or the condensed ring may further be substituted by one or more halogen atoms, cyano groups, hydroxy groups, amino groups, trifluoromethyl groups, C₁ to C₆ alkyl groups, C₁ to C₆ alkoxy groups, C₁ to C₆ alkylthio groups, mono(C₁ to C₆ alkyl)amino groups, or di(C₁ to C₆ alkyl)amino groups; and

wherein when k is 1 and m is 2, then n is not 1.

8. **(currently amended):** The method according to Claim 7, wherein the disease treatable and/or preventable by administration of a CCR3 antagonist ~~The pharmaceutical composition for treating or preventing the disease according to Claim 7, wherein the disease is an allergic disease.~~

9. **(currently amended):** The method according to Claim 7, wherein the disease treatable and/or preventable by administration of a CCR3 antagonist ~~The pharmaceutical composition for treating or preventing the disease according to Claim 7, wherein the disease is asthma, allergic rhinitis, atopic dermatitis, urticaria, contact dermatitis, or allergic conjunctivitis.~~

10. **(currently amended):** The method according to Claim 7, wherein the disease treatable and/or preventable by administration of a CCR3 antagonist ~~The pharmaceutical composition for treating or preventing the disease according to Claim 7, wherein the disease is an inflammatory bowel disease.~~

11. **(currently amended):** The method according to Claim 7, wherein the disease treatable and/or preventable by administration of a CCR3 antagonist ~~The pharmaceutical composition for treating or preventing the disease according to Claim 7, wherein the disease is AIDS.~~